glp-1 agonist therapy information platforms The expanding landscape of medicines GLP-1 for Weight Loss and

Understanding these energy metabolism effects is relevant to research on obesity and metabolic health

Boye K, Sapin H, Ling Poon J, Fernandez Lando L, Huh R, Wang M, et al

High-Priority Interactions: Insulin, Sulfonylureas, and Hypoglycemia The single most common serious adverse event with GLP-1 RA combination therapy is hypoglycemia, and it almost always involves co-prescribed insulin or a sulfonylurea

The discovery of parkin and UCH-L1 mutations, as well as their involvement in the ubiquitin-proteasomal system, ushered in a new age of research into changes in protein processing in dopaminergic cells via both proteasomes and lysosomes (Eldeeb et al., 2022